Core Insights - Dianthus Therapeutics has appointed John C. King as Chief Commercial Officer, bringing over 25 years of experience in biotechnology and complement inhibitors [1][2] - The company is focused on advancing DNTH103, a potential first-line therapy for neuromuscular diseases, with key data expected in the second half of 2025 [2] - Sujay Kango has joined the Board of Directors, contributing over 26 years of experience in the pharmaceutical and biotechnology sectors [3] Company Developments - John C. King previously held significant roles at Alexion Pharmaceuticals and Ra Pharma, where he contributed to the development of blockbuster therapies and led commercial strategies [1][2] - Dianthus is dedicated to developing next-generation antibody complement therapeutics aimed at severe autoimmune diseases [5] - The company is transitioning its Board of Directors, with Tomas Kiselak stepping down [4] Market Position - DNTH103 is positioned as a differentiated therapy with a unique combination of potency, safety, and convenience, targeting diseases like generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN) [2] - The company aims to build a late-stage biotech profile, leveraging the extensive experience of its leadership team to navigate the competitive landscape [2][3]

Company Overview - Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [1][2] - The company aims to design and deliver novel, best-in-class monoclonal antibodies with enhanced selectivity and potency [1] Recent Developments - Dianthus Therapeutics announced its participation in several upcoming investor conferences, indicating active engagement with the investment community [1][2] - CEO Marino Garcia will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, and will also host one-on-one meetings with investors [2] - CFO Ryan Savitz will conduct one-on-one investor meetings at the Jefferies Biotech on the Bay Summit on March 12, 2025 [2]

Dianthus Therapeutics (DNTH) Conference February 06, 2025 09:00 AM ET Company Participants Marino Garcia - President, CEO, Secretary & Director Conference Call Participants Yatin Suneja - Biotechnology Research Analyst Yatin Suneja Good morning, everyone. My name is Yatin Suneja, one of the biotech analysts here at Guggenheim. Welcome to our SMITCAP Biotech Conference. It is my pleasure to introduce our our first presenting company of the day, Dianthus. From the company, we have Marino Garcia, who is the Ch ...

Core Insights - Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [1][2] - The company will participate in healthcare investor conferences in February, with presentations by CEO Marino Garcia [1][3] Company Overview - Dianthus Therapeutics is dedicated to designing and delivering novel, best-in-class monoclonal antibodies with enhanced selectivity and potency [2] - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharmaceutical executives [2] Upcoming Events - The company will host a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6 at 9:00 a.m. ET in New York City [3] - A virtual fireside chat is scheduled for February 12 at 3:20 p.m. ET during the Oppenheimer 35th Annual Healthcare Life Sciences Conference [3]

Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune and inflammatory diseases [3] - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharma executives [3] - Dianthus Therapeutics is dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency [3] Upcoming Event - Dianthus Therapeutics will participate in the 43rd Annual J P Morgan Healthcare Conference [1] - CEO Marino Garcia will present a corporate overview on January 15, 2025, at 9:00 a m PST / 12:00 p m EST in San Francisco [1] - A live webcast of the presentation will be available on the company's website under the "News and Events" section in the Investors section [2] Additional Information - More details about Dianthus Therapeutics can be found on their website at www dianthustx com [4] - The company can also be followed on LinkedIn for updates [4]

Financial Performance - Dianthus Therapeutics, Inc. reported a quarterly loss of $0.74 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.59, representing an earnings surprise of -25.42% [1] - The company posted revenues of $2.17 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 102.61%, compared to revenues of $0.92 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus revenue estimates three times [2] Stock Performance - Shares of Dianthus Therapeutics, Inc. have increased approximately 182.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 24.3% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.65 on revenues of $1.07 million, and for the current fiscal year, it is -$2.28 on revenues of $4.16 million [7] - The estimate revisions trend for the company is mixed, resulting in a Zacks Rank 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Dianthus Therapeutics, Inc. belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [2] - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharmaceutical executives [2] Upcoming Events - The company will participate in several healthcare investor conferences in November and December 2024, including: - Guggenheim Healthcare Innovation Conference on November 11 at 1:30 p.m. ET in Boston, MA [1] - Jefferies Global Healthcare Conference on November 19 at 9:00 a.m. GMT in London [1] - 7th Annual Evercore HealthCONx Conference on December 4 at 10:50 a.m. ET in Coral Gables, FL [1] - Live webcasts of the presentations will be available on the company's website under the "News and Events" section [1]

Dianthus Therapeutics, Inc. (DNTH) shares soared 5.7% in the last trading session to close at $27.99. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4.9% loss over the past four weeks. The growing optimism over the company's lead pipeline candidate DNTH103, which is being developed for treating several autoimmune diseases, like generalized Myasthenia Gravis (gMG), multifocal motor neuropathy (MMN) and chronic inflammatory demyel ...

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.80 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.54, delivering a surprise of -25.58%. Over the last four quarters, the company ...

Its lead investigational candidate is DNTH103, which is being developed for several autoimmune indications, like generalized Myasthenia Gravis (gMG), multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyneuropathy (CIDP). DNTH103 is a monoclonal antibody in clinical development. It is designed to selectively inhibit the active form of the C1s protein, a vital component of the classical complement pathway, which has been clinically validated as a therapeutic target for autoimmune dise ...